Oil prices hold gains amid Russia supply risks; OPEC+ meeting looms
Investing.com - Goldman Sachs has reiterated its Buy rating and $19.00 price target on Carlsmed Inc (NASDAQ:CARL) following the company’s second-quarter results. The target represents significant upside from the current price of $13.69, with analyst targets ranging from $16 to $21.
The investment bank maintained its Street-high revenue estimates for Carlsmed , expressing confidence in the company’s forward growth outlook and potential for further upside. According to InvestingPro data, the company maintains strong financial health with a current ratio of 6.48 and operates with moderate debt levels.
Carlsmed’s second-quarter performance aligned with preliminary results reported in its S-1 filing on July 15. The company’s full-year outlook exceeded expectations, reflecting higher-than-planned surgeon additions in the second quarter and the resulting impact on future revenue performance.
Goldman Sachs noted that all financial and operational metrics are tracking in line with its view that Carlsmed’s recent capital raise should provide sufficient resources for the company to achieve positive adjusted EBITDA and cash flow without requiring additional financing.
The firm’s analysis included revised forecasts based on second-quarter results, the 10-Q filing, inaugural 2025 guidance, commentary on surgeon education and training initiatives, and updated profit and loss assumptions.
In other recent news, Carlsmed Inc. reported a remarkable 99% year-over-year revenue increase for the second quarter of 2025, reaching $12.1 million. This significant growth underscores the company’s strong financial performance during this period. The revenue surge reflects positive investor sentiment and a promising outlook for future growth. These developments are part of recent updates concerning Carlsmed. The company’s financial results have drawn attention from investors and analysts alike. The latest earnings report highlights Carlsmed’s ability to deliver substantial revenue growth. These figures are crucial for investors seeking insights into the company’s financial health and trajectory.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.